A mathematical model for IL-6-mediated, stem cell driven tumor growth and targeted treatment

Area of Science:

• Oncology
• Systems Biology
• Immunology

Background:

• Cancer stem cells (CSCs) drive tumor growth and treatment resistance.
• Interleukin-6 (IL-6) plays a crucial role in CSC self-renewal and survival.
• Targeting CSCs is a key strategy for effective cancer therapy.

Purpose of the Study:

• To develop a multiscale modeling framework for IL-6-mediated CSC-driven tumor growth.
• To quantify the impact of IL-6 on CSC self-renewal, survival, and tumor dynamics.
• To evaluate the efficacy of anti-IL-6 antibody treatment using the model.

Main Methods:

• Developed a computational model integrating cellular and molecular levels.
• Incorporated IL-6 binding kinetics and receptor occupancy.
• Validated model predictions against experimental data from primary tumor xenografts.

Main Results:

• The model accurately correlates with experimental data for tumor xenografts.
• IL-6 significantly influences CSC self-renewal and survival, impacting tumor volume.
• Simulated treatment with tocilizumab (anti-IL-6 receptor antibody) demonstrated tumor reduction.

Conclusions:

• IL-6 blockade is a viable strategy to target CSCs and inhibit tumor growth.
• The developed model provides quantitative insights into IL-6's role in tumorigenesis.
• Low-dose tocilizumab shows potential for sustained tumor growth deceleration.